Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer

Summary

The purpose of this phase II study is to evaluate the safety and efficacy of niraparib and dostarlimab in patients with germline or somatic BRCA 1 or BRCA2 and PALB2 mutated metastatic pancreatic cancer.

General Information

NCT#: NCT04493060
Study ID: MC1841
Trial Phase: Phase II

Trial Sponsor: Mayo Clinic
Therapies Used in This Trial: Niraparib, Dostarlimab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search